ArticleAnnals of hematology2021

Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients-a single-center retrospective study.

Bernard Regidor et al.PubMed ↗Publisher ↗

No numbers read from the abstract.